Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.62 |
| ▸ | DTYMK | P23919 | 4/20 | 0.56 |
| ▸ | TERT | O14746 | 2/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420169 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL30369215 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29376343 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29386416 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29366358 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29376007 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29959424 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL30656494 | 0.99 | F2 (0.61) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29354146 | 0.98 | F2 (0.60) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29361881 | 0.98 | F2 (0.60) | F2DTYMKTERTP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA INC (US) | 2024-06-27 | — | — | US | claimed |
| EP-4326329-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Civi Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-12-01 | — | — | US | claimed |
| WO-2022226217-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | claimed |
| US-12625133-B2 | Chemical denaturation for oligonucleotide analysis | WATERS TECHNOLOGIES CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4720277-A1 | OLIGONUCLEOTIDE EXTRACTION METHOD AND KIT CROSS-REFERENCE TO RELATED APPLICATIONS | Waters Technologies Corporation (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4648873-A1 | DIPODAL SILANE BONDED SORBENTS FOR SOLID PHASE EXTRACTION AND USE THEREOF FOR OLIGONUCLEOTIDE EXTRACTION | Waters Technologies Corporation (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250255985-A1 | PARVOVIRUS ITR-BASED GENE DELIVERY VECTOR SYSTEM | MODEX THERAPEUTICS, INC. | 2025-08-14 | — | — | US | disclosed |
| US-12359191-B2 | Polyanionic acids to improve recovery and minimize system loss | WATERS TECHNOLOGIES CORPORATION (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250161481-A1 | TARGETED LNP DELIVERY | MODEX THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| WO-2025096824-A1 | TARGETED LNP DELIVERY | MODEX THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20220370438-A1 | METHOD FOR INDUCING A SUSTAINED IMMUNE RESPONSE | CYTOCOM SUBSIDIARY INC (US) | 2022-11-24 | — | — | US | disclosed |
| EP-4090741-A1 | IMPROVED PERFORMANCE AND DYNAMIC RANGE FOR OLIGONUCLEOTIDE BIOANALYSIS THROUGH REDUCTION OF NON-SPECIFIC BINDING | Waters Technologies Corporation (US) | 2022-11-23 | — | — | EP | disclosed |
| WO-2022226217-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-4070102-A1 | POLYPHOSPHONIC ACIDS FOR IMPROVING RECOVERY AND MINIMIZING SYSTEM LOSS | Waters Technologies Corporation (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115003808-A | Improving performance and dynamic range of oligonucleotide bioanalysis by reducing non-specific binding | 沃特世科技公司 | 2022-09-02 | — | — | CN | disclosed |
| US-11419865-B2 | Method for inducing a sustained immune response | CYTOCOM INC (US) | 2022-08-23 | — | — | US | disclosed |
| CN-114787622-A | Polyphosphonic acids for improved recovery and minimizing system losses | 沃特世科技公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161481-A1 | TARGETED LNP DELIVERY | CD4, LCP2, CD2 | F2 4815/4885DTYMK 2206/4885TERT 1407/4885 |
| US-12625133-B2 | Chemical denaturation for oligonucleotide analysis | DNASE1, RNGTT, RNASE1 | F2 1620/4885DTYMK 71/4885TERT 30/4885 |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885DTYMK 437/4885TERT 3199/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | F2 1924/4885DTYMK 966/4885TERT 4697/4885 |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885DTYMK 437/4885TERT 3199/4885 |
| US-20250387363-A1 | LIQUID EPINEPHRINE PRODRUG FORMULATIONS AND LIQUID EPINEPHRINE FORMULATIONS | ADRB3, ADRB2, ADRB1 | F2 1967/4885DTYMK 2059/4885TERT 2375/4885 |
| US-20250255985-A1 | PARVOVIRUS ITR-BASED GENE DELIVERY VECTOR SYSTEM | GPR68, LARP7, INCENP | F2 4859/4885DTYMK 1606/4885TERT 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.